1PHIA.MI
Strong BuyFull HouseAI neutralKoninklijke Philips N.V. · Healthcare · Netherlands · $23.2B cap · $38K/day traded
EUR 24.26 -0.3% · close 30 Oct · scored 3 Nov
Full House: Strong business, sensible price, and the market agrees.
As of 3 Nov 2026, MoatMap's StockRank for Koninklijke Philips N.V. (1PHIA.MI) is 96/100, ranked against 24,000+ stocks in 35 markets (Quality 62, Value 69, Momentum 73, each scored against its sector).
Does StockRank work? Each month we publish how each tenth of the ranking did, whichever way it went. See the record →
Philips makes hospital imaging, patient monitoring and personal health products. It beat expectations in the second quarter but order intake disappointed, and forward estimates slipped 1.6% in four weeks. The company is still rebuilding trust and margins after the Respironics sleep-apnoea device recall and faces weaker demand in China, making this a recovery story rather than a proven compounder.
ABOUT KONINKLIJKE PHILIPS N.V.
Read
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.8B | 18.2B | 18.0B | 17.8B | 0.0% | 17.6B | 17.9B | 18.8B | 2.5% |
| EPS (EUR) | -1.68 | -0.49 | -0.75 | 0.94 | — | 1.15 | — | — | — |
| Shares | 952.3M | 937.4M | 925.0M | 951.3M | -0.1% | 977.4M | — | — | — |
| Debt | 7.3B | 7.3B | 7.5B | 7.8B | 2.1% | 7.4B | — | — | — |
| Equity | 13.2B | 12.0B | 12.0B | 11.0B | -6.1% | — | — | — | — |
| Op CF | -173.0M | 2.1B | 1.6B | 1.2B | -25.9% | 2.3B | — | — | — |
| Inv CF | -1.5B | -636.0M | -573.0M | -737.0M | — | — | — | — | — |
| Fin CF | 500.0M | -848.0M | -496.0M | 107.0M | — | — | — | — | — |
No new 52-week low for 3 weeks, 21% above that low, but not back above a rising 50-day average.
The Momentum score still reads 73: it looks back six months, so it has not caught up with this fall.
Calmer than 78% of stocks we rank over the past year (volatility 27% a year).
How this is worked out
StockRank weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 1PHIA.MI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 1PHIA.MI | Koninklijke Philips N.V.(you) | $23.2B | 96 | Strong Buy |
| QIA.DE | Qiagen N.V. | $10.4B | 89 | Strong Buy |
| ARGX.BR | argenx SE | $55.1B | 70 | Buy |
| RDC.DE | Redcare Pharmacy NV | $1.8B | 67 | Buy |
| PHARM.AS | Pharming Group N.V. | $803M | 75 | Buy |
| NAMS | NewAmsterdam Pharma Company N.V. | $2.3B | 10 | Strong Sell |
| QURE | uniQure N.V. | $1.6B | 17 | Strong Sell |
| PRQR | ProQR Therapeutics N.V. | $182M | 17 | Strong Sell |
| ONWD.BR | Onward Medical N.V. | $161M | 12 | Strong Sell |
Peer medians: ROE 8.7% · P/E 31.7x · Gross margin 75.4%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.